TUSC2 transient expression combined with AF and erlotinib reduced viability of Calu-6, Calu-3, and H522 by 78%, 64%, and 75% respectively, which was more effective than any other tested treatments. This evidence concerns the gene TUSC2 and atrial fibrillation.